- Home
- NCA vs DCTH Comparison
NCA vs DCTH Comparison
Compare NCA & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCA
- DCTH
- Stock Information
- Founded
- NCA 1987
- DCTH 1988
- Country
- NCA United States
- DCTH United States
- Employees
- NCA N/A
- DCTH 76
- Industry
- NCA Investment Managers
- DCTH Medical/Dental Instruments
- Sector
- NCA Finance
- DCTH Health Care
- Exchange
- NCA Nasdaq
- DCTH Nasdaq
- Market Cap
- NCA 279.1M
- DCTH 426.3M
- IPO Year
- NCA N/A
- DCTH N/A
- Fundamental
- Price
- NCA $8.56
- DCTH $11.52
- Analyst Decision
- NCA
- DCTH Strong Buy
- Analyst Count
- NCA 0
- DCTH 4
- Target Price
- NCA N/A
- DCTH $24.00
- AVG Volume (30 Days)
- NCA 59.6K
- DCTH 850.4K
- Earning Date
- NCA 01-01-0001
- DCTH 08-04-2025
- Dividend Yield
- NCA 3.92%
- DCTH N/A
- EPS Growth
- NCA N/A
- DCTH N/A
- EPS
- NCA N/A
- DCTH N/A
- Revenue
- NCA N/A
- DCTH $53,850,000.00
- Revenue This Year
- NCA N/A
- DCTH $155.42
- Revenue Next Year
- NCA N/A
- DCTH $37.93
- P/E Ratio
- NCA N/A
- DCTH N/A
- Revenue Growth
- NCA N/A
- DCTH 1068.87
- 52 Week Low
- NCA $7.77
- DCTH $7.17
- 52 Week High
- NCA $9.12
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- NCA 52.68
- DCTH 32.83
- Support Level
- NCA $8.51
- DCTH $12.11
- Resistance Level
- NCA $8.62
- DCTH $14.15
- Average True Range (ATR)
- NCA 0.08
- DCTH 0.57
- MACD
- NCA 0.00
- DCTH -0.16
- Stochastic Oscillator
- NCA 54.11
- DCTH 9.67
About NCA Nuveen California Municipal Value Fund
Nuveen California Municipal Value Fund Inc is a diversified closed-end management investment company. Its primary objective is to provide current income exempt from regular federal and California income taxes. The fund's secondary objective is to enhance portfolio value relative to the California municipal bond market by investing in tax-exempt California municipal securities that the Fund's investment adviser and/or the Fund's sub-adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.